-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ipilimumab in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ipilimumab in Melanoma Drug Details: Ipilimumab (Yervoy, Winglore) is a recombinant, human monoclonal...
-
Product Insights
NewSecondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024
Empower your strategies with our Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Secondary progressive multiple sclerosis (SPMS) is a form of MS that follows relapsing-remitting MS (RRMS). In RRMS, people experience periods of relapses, when symptoms get worse, and remissions, when symptoms get better. In SPMS, symptoms gradually worsen over time without any clear relapses or remissions. SPMS usually occurs 10 to 15 years after the first MS symptoms, but it...
-
Product Insights
NewThymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024
Empower your strategies with our Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024 report and make more profitable business decisions. Thymoma, also known as thymic epithelial tumor, is a rare type of cancer that originates in the thymus gland, a small organ located behind the breastbone and in front of the heart. The thymus gland plays a role in the development of certain immune cells and is most active during childhood but gradually becomes less active with age. Thymomas are...
-
Product Insights
NewMalignant Pleural Mesothelioma – Drugs In Development, 2024
Empower your strategies with our Malignant Pleural Mesothelioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant pleural mesothelioma is a rare cancer of the lining around the lungs, called the pleura. It is caused by asbestos fibers. After inhalation, the fibers can embed in the pleura, causing inflammation and scarring. Over time, these processes can lead to the development of mesothelioma tumors. The most common symptoms of pleural mesothelioma include difficulty breathing, swelling, back pain, and...
-
Product Insights
NewMacular Edema – Drugs In Development, 2024
Empower your strategies with our Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the...
-
Product Insights
NewNeuroblastoma – Drugs In Development, 2024
Empower your strategies with our Neuroblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands before spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include a lump in the abdomen or chest, weakness, bone pain, breathing problems, dark...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBA-1535 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CBA-1535 in Solid Tumor Drug Details: CBA-1535 (TB-535H) is under development for the treatment of...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC (malignancy) originates in the tissues of the lungs or the cells lining the airways. Symptoms usually occur in the later stages of the disease, and include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness, and unintentional weight...